AIMEDBIO
IR
ENG
KOR
ABOUT US
Overview
Leadership
Corporate Governance
R&D
AimedBio’s Drug Development
P-ADC™
Pipeline
IR
Disclosure
Stock
Financial Information
PR
Notice
Press Release
Data Room
CAREERS
Our Culture
Disclosure
48 posts
NO.
Title
Date
Author
38
Reporting reasons for holding general shareholders' meeting on the most concentrated date
2026-03-11
에임드바이오
37
Resolutions for Convocation of General Meeting of Shareholders
2026-03-11
에임드바이오
36
Notice on Investor Relations
2026-02-27
에임드바이오
35
Notice on Investor Relations
2026-02-27
에임드바이오
34
30% or More Change in Sales or Profit/Loss(15% or more in the case of large-scale corporations)
2026-02-06
에임드바이오
33
Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure)
2026-02-06
에임드바이오
32
Report on status of specific securities, etc. owned by executives and major shareholders
2026-02-05
인터베스트
31
Report on significant holdings of stocks, etc. (Short form)
2026-02-05
인터베스트
30
Relocation of Corporate Headquarters
2026-01-30
에임드바이오
29
Report on status of specific securities, etc. owned by executives and major shareholders
2026-01-09
허남구
Reporting reasons for holding general shareholders' meeting on the most concentrated date
에임드바이오
2026-03-11
Resolutions for Convocation of General Meeting of Shareholders
에임드바이오
2026-03-11
Notice on Investor Relations
에임드바이오
2026-02-27
Notice on Investor Relations
에임드바이오
2026-02-27
30% or More Change in Sales or Profit/Loss(15% or more in the case of large-scale corporations)
에임드바이오
2026-02-06
Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure)
에임드바이오
2026-02-06
Report on status of specific securities, etc. owned by executives and major shareholders
인터베스트
2026-02-05
Report on significant holdings of stocks, etc. (Short form)
인터베스트
2026-02-05
Relocation of Corporate Headquarters
에임드바이오
2026-01-30
Report on status of specific securities, etc. owned by executives and major shareholders
허남구
2026-01-09
1
2
3
4
5
